tarenflurbil

Tarenflurbil is the R-enantiomer of flurbiprofen and was developed as an orally active small molecule for the treatment of Alzheimer's disease and other conditions. Unlike traditional nonsteroidal anti-inflammatory drugs (NSAIDs), tarenflurbil lacks significant cyclooxygenase (COX) inhibitory activity at therapeutic concentrations. Its primary mechanism is as a selective amyloid lowering agent (SALA), modulating gamma-secretase activity to reduce production of amyloid beta 42 (Aβ42), a peptide implicated in Alzheimer's disease pathology[2][3][4][8]. Tarenflurbil also acts as an inhibitor of nuclear factor kappa B (NF-kappa B) and transcription factor AP-1, leading to downregulation of cyclin D1 expression and cell cycle arrest in tumor cells[1][5]. The drug was investigated for Alzheimer's disease but development was discontinued after phase 3 trials failed to show efficacy; it has also been studied in prostate cancer, pain, inflammation, and multiple sclerosis[2][4][5].

Brand names

Flurizan

Other names

tarenflurbil